EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Subcutaneous infliximab in Crohn’s disease patients with previous immunogenic failure of intravenous infliximab

Julia Husman, Karin Černá, Katja Matthes, Maximilian Gilger, Maia Arsova, Alexandra Schmidt, Nadia Winzer, Anna-Magdalena Brosch, Franz Brinkmann, Jochen Hampe, Sebastian Zeissig, Milan Lukáš und 1 weitere

International Journal of Colorectal Disease · 2024

DOI: 10.1007/s00384-024-04727-3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Colorectal Disease, 2024. Verfasst von Julia Husman und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine 1, University Hospital Carl Gustav Carus Dresden, Technische Universität (TU), Fetscherstrasse 74, 01307, Dresden, Germany. Hauptthemen laut MEDLINE: Crohn Disease, Infliximab. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Technische Universität Dresden.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Immunogenicity is a major reason for secondary loss of response to infliximab (IFX). Recent work suggested potentially lower immunogenicity of subcutaneous (SC) compared to intravenous (IV) IFX. However, it is unknown whether re-exposure to IFX SC after secondary loss of response and immunogenicity to its intravenous formulation is safe and effective.

Methods

In a retrospective cohort study conducted at two medical centers, patients with clinically (Harvey-Bradshaw Index ≥ 5) and/or biochemically (fecal calprotectin > 250 µg/g) active Crohn’s disease (CD) and previous immunogenic failure of IFX IV underwent exposure to IFX SC. Harvey-Bradshaw Index, fecal calprotectin, IFX serum concentration, and anti-drug antibodies were assessed until month 12.

Results

Twenty CD patients were included. The majority of patients (90%) had previous treatment with three or more biologics. Fifteen (75%) and ten (50%) of 20 patients continued IFX SC treatment until months 6 and 12, respectively. No immediate hypersensitivity reactions were observed. Two patients discontinued IFX SC treatment because of delayed hypersensitivity at week 2 and week 4. IFX serum concentrations increased from baseline to month 12, while anti-drug antibody levels decreased. Combined clinical and biochemical remission at month 12 was observed in seven of 20 patients (35%).

Conclusion

Subcutaneous infliximab treatment of Crohn’s disease patients with previous immunogenic failure of intravenous infliximab was well tolerated and effective in a cohort of patients with refractory Crohn’s disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Crohn DiseaseInfliximabHumansFemaleMaleAdultInjections, SubcutaneousAdministration, IntravenousMiddle AgedRetrospective StudiesLeukocyte L1 Antigen ComplexFecesTreatment FailureYoung Adult

Stichwörter der Autor:innen

CT-P13Immunogenic failureRefractory Crohn’s diseaseSubcutaneous infliximab

Substanzen

InfliximabLeukocyte L1 Antigen Complex

Autor:innen und Institutionen

  • Department of Medicine 1, University Hospital Carl Gustav Carus Dresden, Technische Universität (TU), Fetscherstrasse 74, 01307, Dresden, Germany.
  • Clinical and Research Center for Inflammatory Bowel Disease ISCARE and First Faculty of Medicine, Charles University, Prague, Czech Republic.
  • Center for Regenerative Therapies Dresden (CRTD), Technische Universität (TU), Dresden, Germany.
  • Department of Internal Medicine A, University Medicine Greifswald, Greifswald, Germany.
  • Department of Medicine 1, University Hospital Carl Gustav Carus Dresden, Technische Universität (TU), Fetscherstrasse 74, 01307, Dresden, Germany. renate.schmelz@ukdd.de.

Förderung

  • Technische Universität Dresden

Zitieren

APA

Husman, J., Černá, K., Matthes, K., Gilger, M., Arsova, M., Schmidt, A., Winzer, N., Brosch, A. M., Brinkmann, F., Hampe, J., Zeissig, S., Lukáš, M., & Schmelz, R. (2024). Subcutaneous infliximab in Crohn’s disease patients with previous immunogenic failure of intravenous infliximab. International Journal of Colorectal Disease. https://doi.org/10.1007/s00384-024-04727-3

Vancouver

Husman J, Černá K, Matthes K, Gilger M, Arsova M, Schmidt A, et al. Subcutaneous infliximab in Crohn’s disease patients with previous immunogenic failure of intravenous infliximab. International Journal of Colorectal Disease. 2024. doi:10.1007/s00384-024-04727-3

BibTeX
@article{Husman2024,
  author = {Husman, Julia and Černá, Karin and Matthes, Katja and Gilger, Maximilian and Arsova, Maia and Schmidt, Alexandra and Winzer, Nadia and Brosch, Anna-Magdalena and Brinkmann, Franz and Hampe, Jochen and Zeissig, Sebastian and Lukáš, Milan and Schmelz, Renate},
  title = {Subcutaneous infliximab in Crohn’s disease patients with previous immunogenic failure of intravenous infliximab},
  journal = {International Journal of Colorectal Disease},
  year = {2024},
  doi = {10.1007/s00384-024-04727-3}
}
Kostenlos starten →